Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Cited by (843)

Items 201–300 of 843

1. Treatment of advanced non-small-cell lung cancer
   Kumar Prabhash, Amish D. Vora, Sewanti Atul Limaye, Tarini Prasad Sahoo, Ullas Batra, Shekhar Patil, Vijay Patil, Vanita Noronha, Bharat Bhosale, Nirmal Vivek Raut et al. · 2021 · Cancer Research Statistics and Treatment
2. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
   Valerie W. Rusch, Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura, Dan J. Raz, Karen L. Reckamp, Robert E. Merritt, Dwight Hall Owen et al. · 2022 · Journal of Thoracic and Cardiovascular Surgery
3. Biomarkers for immunotherapy resistance in non-small cell lung cancer
   Catriona Rother, Tom John, Annie Ngai Man Wong · 2024 · Frontiers in Oncology
4. Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis
   Hongming Zhang, Liting Guo, Jibei Chen · 2020 · OncoTargets and Therapy
5. PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
   Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Tsung‐Ying Yang, Kun‐Chieh Chen, Kang‐Yi Su, Sung‐Liang Yu, Jeremy J.W. Chen, Yen-Hsiang Huang, Gee‐Chen Chang · 2022 · Scientific Reports
6. Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
   Ilaria Attili, Antonio Passaro, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Filippo de Marinis · 2023 · Cancer Treatment Reviews
7. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
   Chao Zhang, Yu-Xuan Sun, Dingcheng Yi, Ben‐Yuan Jiang, Li‐Xu Yan, Ze-Dao Liu, Lishan Peng, Wenjie Zhang, Hao Sun, Zhiyong Chen et al. · 2024 · Cell Reports Medicine
8. Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best‐practice guide
   Adam H. Fox, Mizuki Nishino, Raymond Uyiosa Osarogiagbon, M. Patricia Rivera, Lauren S. Rosenthal, Robert Allen Smith, Farhood Farjah, Lynette Marie Sholl, Gerard A. Silvestri, Bruce Evan Johnson · 2023 · CA A Cancer Journal for Clinicians
9. Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
   Neal S. McCall, Adam Paul Dicker, Bo Lü · 2018 · Clinical Cancer Research
10. Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
    Yosuke Miura, Noriaki Sunaga · 2018 · Cancers
11. Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
    Herbert Ho-Fung Loong, Sui-chun Sampson Kwan, Tony S.K. Mok, Yat Ming Lau · 2018 · Current Treatment Options in Oncology
12. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
    Luigi Cavanna, Chiara Citterio, Elena Orlandi · 2019 · Oncotarget
13. When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
    Laurent Mhanna, Nicolas Marie Guibert, Julie Milia, Julien Mazières · 2019 · Current Treatment Options in Oncology
14. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front
    Maria Saigí, Juan J. Alburquerque-Béjar, Montse Sánchez‐Céspedes · 2019 · Oncogene
15. Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR ‐mutant non‐small cell lung cancer
    Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Motohiro Izumi, Koichi Ogawa, Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka et al. · 2019 · Cancer Science
16. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis
    Jiayan Chen, Wanjun Lu, Mo Chen, Zijing Cai, Ping Zhan, Xin Liu, Suhua Zhu, Mingxiang Ye, Tangfeng Lv, Jiawen Lv et al. · 2024 · Therapeutic Advances in Medical Oncology
17. Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
    Alex Friedlaender, Giuseppe Luigi Banna, Sandip H. Patel, Alfredo Addeo · 2019 · Current Treatment Options in Oncology
18. Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
    Christoph Jakob Ackermann, Gustavo Trautman Stock, Rebecca Yin Tay, Mohammed Adam Ibrahim Dawod, Fábio Gomes, Raffaele Califano · 2019 · OncoTargets and Therapy
19. Proteolysis targeting chimera ( PROTAC ) for epidermal growth factor receptor enhances anti‐tumor immunity in non‐small cell lung cancer
    Kai Wang, Hongping Zhou · 2020 · Drug Development Research
20. Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
    Chao Zhang, Huafei Chen, Yan Shi, Lin Wu, Li‐Xu Yan, Xiaolong Yan, Dongsheng Yue, C. Xu, Min Zheng, Jisheng Li et al. · 2022 · npj Precision Oncology
21. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
    Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, Letícia Ferro Leal, Lídia Maria Rebolho Batista Arantes · 2023 · International Journal of Molecular Sciences
22. Immunotherapy strategy of EGFR mutant lung cancer.
    Shaorong Yu, Delin Liu, Bo Shen, Meiqi Shi, Jifeng Feng · 2018 · Europe PMC (PubMed Central)
23. Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
    Khi Pin Chua, Yvonne H.F. Teng, Aaron C. Tan, Angela Maria Takano, Jacob J.S. Alvarez, Rahul R. Nahar, Neha Rohatgi, Gillianne Geet Yi Lai, Zaw Win Aung, Joe Poh-Sheng Yeong et al. · 2021 · Clinical Cancer Research
24. EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
    Huayan Huang, Xiaokuan Zhu, Yongfeng Yu, Ziming Li, Yi Yang, Liliang Xia, Shun Lü · 2024 · Journal of Translational Medicine
25. The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base
    Xiao‐Dong Jiao, Xi He, Bao‐Dong Qin, Ke Liu, Ying Wu, Jun Liu, Ting Hou, Yuan‐Sheng Zang · 2019 · Journal of Thoracic Disease
26. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Danielle Brazel, Gianna Kroening, Misako Nagasaka · 2022 · BioDrugs
27. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy
    Weiting Hu, Qiurui Zhang, Ze Zhang, Xuan He, Min Zhou, Yi Maggie Guo, Xiaofei Wang · 2023 · Frontiers in Immunology
28. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
    Natalie I. Vokes, Kelsey Pan, Xiuning Le · 2023 · Therapeutic Advances in Medical Oncology
29. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
    Saad A. Khan, Bo Ci, Yang Xie, David E. Gerber, Muhammad Shaalan Beg, Steven I. Sherman, Maria E. Cabanillas, Naifa Lamki Busaidy, Barbara Ann Burtness, Andreas M. F. Heilmann et al. · 2019 · Head & Neck
30. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations
    Diego Erich Kauffmann-Guerrero, Amanda Tufman, Kathrin Kahnert, Benjamin A. Bollmann, Simone Reu, Zulfiya Syunyaeva, Christian P. Schneider, Farkhad Manapov, Rudolf Maria Huber, Heiko A Golpon · 2020 · Oncology Research and Treatment
31. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study
    Akihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, Akito Fukuda, Satoshi Watanabe, Naoya Nishioka, Takayuki Takeda, Yusuke Chihara, Shinnosuke Takemoto, Taishi Harada et al. · 2021 · Translational Lung Cancer Research
32. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
    Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu · 2023 · Cancers
33. Albumin–globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer
    Yu Nakanishi, Takeshi Masuda, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Takahiro Mimae, Taku Nakashima, Shintaro Miyamoto, Yasuhiro Tsutani, Hiroshi Iwamoto et al. · 2019 · International Journal of Clinical Oncology
34. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
    Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino et al. · 2019 · Therapeutic Advances in Medical Oncology
35. Development of novel radiolabeled antibody-conjugated graphene quantum dots for targeted in vivo breast cancer imaging and biodistribution studies
    Raziyeh Ganji Arjenaki, Ghazaleh Samieepour, Seyed Esmaeil Sadat-Ebrahimi, Morteza Pirali Hamedani, Mostafa Saffari, Mohammad Seyedhamzeh, Ali Naghi Kamali, Atena Najdian, Mehdi Shafiee Ardestani · 2023 · Arabian Journal of Chemistry
36. Nivolumab in non-small-cell lung cancer with EGFR mutation
    Hironori Yoshida, Y.H. Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Yuto Yasuda, Tomoko Yamamoto Funazo, Toyohiro Hirai · 2017 · Annals of Oncology
37. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light
    Christoph Jakob Ackermann, Martin Reck, Luis G Paz-Ares, Fabrice Barlési, Raffaele Califano · 2019 · Lung Cancer
38. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
    Masaoki Ito, Carles Codony, Jordi Codony‐Servat, David Lligé, Imane CHAIB-OUKADOUR, Xiaoyan Sun, Miao Jing, Rongwei Sun, Xueting Cai, Alberto Verlicchi et al. · 2019 · Cell Communication and Signaling
39. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
    Daniel Sentana‐Lledo, Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Paul A. VanderLaan, Daniel Botelho Costa · 2023 · Translational Lung Cancer Research
40. Tenofovir-induced osteomalacia.
    Daniel Wanner, Alan Tyndall, Ulrich Andreas Walker · 2009 · PubMed
41. Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer
    Juanfeng Lao, Huiting Xu, Zibin Liang, Changliang Luo, Liuyang Shu, Yuping Xie, Yongjian Wu, Yanrong Hao, Yulin Yuan · 2023 · Immunobiology
42. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
    Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, Mattia Alberto Di Civita, Andrea Torchia, Raffaele Giusti, Alain Jonathan Gelibter, Michela Roberto, Monica Verrico, Enrico Melis et al. · 2023 · Critical Reviews in Oncology/Hematology
43. Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies
    Anthony M. Musolf, Claire L. Simpson, Mariza de Andrade, Diptasri M. Mandal, Colette Gaba, Ping Yang, Yafang Li, Ming You, Elena Y. Kupert, Marshall W. Anderson et al. · 2017 · Genes
44. Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells
    Jordi Codony‐Servat, Silvia García-Román, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Ana A. Giménez-Capitán, Santiago Viteri, Andrés Felipe Cardona, Erik d'Hondt, Niki Karachaliou, Rafael Rosell · 2018 · Journal of Thoracic Oncology
45. Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
    Wei Liu, Lei Zhang, Zhiming Xiu, Jian Guo, Liye Wang, Yue Zhou, Yang Jiao, Meiyan Sun, Jianhui Cai · 2020 · OncoTargets and Therapy
46. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
    Sangtian Liu, Fengying Wu, Xuefei Li, Chao Zhao, Yijun Jia, Keyi Jia, Ruoshuang Han, Meng Qiao, Wei Li, Jia Yu et al. · 2021 · Frontiers in Oncology
47. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
    Nicholas Giustini, Lyudmila A. Bazhenova · 2021 · Lung Cancer Targets and Therapy
48. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
    Zhen Wang, Lingyun Wei, Jing Li, Han Zhou, Si Li, Dongsheng Chen, Yangyang Yu, Lele Zhao, Xixu Zhu, Yong Song · 2021 · Translational Lung Cancer Research
49. Pan-Cancer Molecular Characterization of m6A Regulators and Immunogenomic Perspective on the Tumor Microenvironment
    Jie Zhu, Jiani Xiao, Min Wang, Daixing Hu · 2021 · Frontiers in Oncology
50. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment
    Jinsong Zhang, Natalie I. Vokes, Man Li, Jiachen Xu, Hua Bai, Jie Wang, Zhijie Wang, Jianjun Zhang · 2024 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
51. Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective analysis
    Minjiang Chen, Qiang Li, Yan Xu, Jing Zhao, Li Zhang, Lijuan Wei, Wei Zhong, Mengzhao Wang · 2020 · Thoracic Cancer
52. Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
    So Yeon Kim, Balázs Halmos · 2020 · Lung Cancer Management
53. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
    Lin Ma, Bowen Diao, Zhaoqin Huang, Bin Wang, Jinming Yu, Xiangjiao Meng · 2021 · 癌症：英文版
54. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data
    Shaoqing Liu, Qian-Jie Tang, Jianwen Huang, Meixiao Zhan, Wei Zhao, Xiangyu Yang, Yong Li, Lige Qiu, Fujun Zhang, Ligong Lu et al. · 2021 · Aging
55. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
    Shota Omori, Hirotsugu Kenmotsu, Masato Abe, Reiko Watanabe, Takashi Sugino, Haruki Kobayashi, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tetsuhiko Taira et al. · 2018 · International Journal of Clinical Oncology
56. Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
    Ryota Shibaki, Shuji Murakami, Yuki Shinno, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noriko Motoi, Noboru Yamamoto et al. · 2019 · Thoracic Cancer
57. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma
    Yan Chen, Ran Hu, Xiaoyou Li, Shi Zhongyuan, Hao Tian, Jifeng Feng, Shaorong Yu · 2020 · Pathology - Research and Practice
58. Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer
    Naleen Raj Bhandari, Lisa M. Hess, Yimei Han, Yajun Emily Zhu, Anthony N. Sireci · 2021 · Immunotherapy
59. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma
    Takahiro Hongo, Hidetaka Yamamoto, Rina Jiromaru, Ryuji Yasumatsu, Ryosuke Kuga, Yui Nozaki, Kazuki Hashimoto, Mioko Matsuo, Takahiro Wakasaki, Akihiro Tamae et al. · 2021 · Modern Pathology
60. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
    Dong‐Wan Kim, Sang‐We Kim, D. Ross Camidge, Catherine A. Shu, Kristen Ashley Marrone, Xiuning Le, Collin Michael Blakely, Keunchil Park, Gee‐Chen Chang, Sandip Pravin Patel et al. · 2023 · Journal of Thoracic Oncology
61. 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One
    R Carvajal, T Sato, A Shoushtari, J Sacco, P Nathan, M Orloff, P Corrie, N Steven, J Evans, J Infante et al. · 2017 · Journal for ImmunoTherapy of Cancer
62. Oncogene-addicted non-small cell lung cancer and immunotherapy
    Georgios Tsakonas, Simon Ekman · 2018 · Journal of Thoracic Disease
63. New Frontiers for Molecular Pathology
    Joanna J. Domagala-Kulawik · 2019 · Frontiers in Medicine
64. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer
    Katsuhiro Yoshimura, Yusuke Inoue, Kazuo Tsuchiya, Masato Karayama, Hidetaka Yamada, Yuji Iwashita, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Naoki Inui et al. · 2020 · Lung Cancer
65. Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics
    Wei Guo, Sijin Sun, Lei Guo, Peng Song, Xuemin Xue, Hao Zhang, Guochao Zhang, Renda Li, Yibo Gao, Bin Qiu et al. · 2020 · DNA and Cell Biology
66. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis
    Shira Peleg Hasson, Benjamin Salwen, Ayelet Sivan, Sivan Shamai, Ravit Geva, Ofer Merimsky, Ari Raphael, Haim Shmilovich, Yonatan Moshkovits, Livia Kapusta et al. · 2020 · Clinical Research in Cardiology
67. Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response
    Jiani Wu, Dongqiang Zeng, Shimeng Zhi, Zilan Ye, Wenjun Qiu, Na Huang, Li Sun, Chunlin Wang, Zhenzhen Wu, Jianping Bin et al. · 2021 · Journal of Translational Medicine
68. B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression
    Youwei Lu, Fengying Wu, Qiuyi Cao, Yu Sun, Moli Huang, Jing Xiao, Bin Zhou, Liang Zhang · 2021 · Oncogene
69. Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial
    Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Alfredo Addeo, Giuseppe Luigi Banna, David James Pinato · 2022 · Cancer
70. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
    Se‐Hoon Lee, Jessica Menis, T.M. Kim, Hye Ryun Kim, Caicun Zhou, Sri Kurniawati, K. Prabhash, H. Hayashi, D.D.-W. Lee, Marcelo Severino Bulauitan Imasa et al. · 2024 · ESMO Open
71. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
    Karim Rihawi, Francesco Gelsomino, Francesca Sperandi, Barbara Melotti, Michelangelo Fiorentino, Laura Casolari, Andrea Ardizzoni · 2017 · Therapeutic Advances in Respiratory Disease
72. Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review
    Bryan T. Oronsky, Patrick Ma, Tony R. Reid, Pedro Cabrales, Michelle Lybeck, Arnold L. Oronsky, Neil C. Oronsky, Corey Allan Carter · 2017 · Neoplasia
73. Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice
    Raffaele Califano, Rohit Lal, Conrad R. Lewanski, Marianne C. Nicolson, Christian H. H. Ottensmeier, Sanjay Popat, Matthew J. Hodgson, Pieter E. Postmus · 2018 · Future Oncology
74. Durvalumab in NSCLC: latest evidence and clinical potential
    Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis G Paz-Ares · 2018 · Therapeutic Advances in Medical Oncology
75. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena, Pawan Kumar Singh, Prabhat Singh Malik, Navneet Singh · 2020 · Current Treatment Options in Oncology
76. Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
    Namita Sharma, Stephen L. Graziano · 2018 · Cancer Treatment Reviews
77. Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
    Alexander Gavralidis, Justin F. Gainor · 2020 · The Cancer Journal
78. Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
    Joanna Kapeleris, Majid Ebrahimi Warkiani, Arutha Kulasinghe, Ian Vela, Liz Kenny, Rahul Ladwa, Kenneth John O'Byrne, Chamindie Punyadeera · 2022 · Frontiers in Oncology
79. Impact of smoking cessation duration on lung cancer mortality: A systematic review and meta-analysis
    Hongkun Lai, Quanzhen Liu, Q Y Ye, Ziyang Liang, Zhiwei Long, Yinghong Hu, Qianlong Wu, Mei Jiang · 2024 · Critical Reviews in Oncology/Hematology
80. Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
    Dong Kyu Oh, Wonjun Ji, Woo Sung Kim, Chang‐Min Choi, Shinkyo Yoon, Jin Kyung Rho, Jae Cheol Lee · 2019 · PLoS ONE
81. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer
    Michael Rahman Shafique, Tawee Tanvetyanon · 2019 · Expert Opinion on Biological Therapy
82. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings
    Mounika Goruganthu, Anil Shanker, Mikhail M. Dikov, David Paul Carbone · 2020 · Frontiers in Immunology
83. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
    Hao Dong, Yihang Qi, Xiangyi Kong, Zhongzhao Wang, Yi Fang, Jing Wang · 2022 · Frontiers in Pharmacology
84. Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
    Chun­yan Shi, Yan Wang, Jianxin Xue, Xiaojuan Zhou · 2022 · Frontiers in Immunology
85. Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy
    Yuli Ge, Qiong Zhou, Fan Pan, Rui Wang · 2025 · International Journal of Nanomedicine
86. Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
    Silvia Vecchiarelli, Francesco Passiglia, Armida D’Incecco, Marianna Gallo, Antonella De Luca, Elisa Rossi, Federica D’Incà, Gabriele Minuti, Lorenza Maria Landi, Chiara Bennati et al. · 2018 · Oncotarget
87. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis
    Jacques Raphael, Anupam Batra, Gabriel Boldt, Prakesh S. Shah, Phillip Blanchette, George Rodrigues, Mark David Vincent · 2020 · Clinical Lung Cancer
88. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi et al. · 2021 · Scientific Reports
89. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
    Yonina R. Murciano‐Goroff, Terry Pak, Sebastián Mondaca, Jessica R. Flynn, Joseph Montecalvo, Natasha Rekhtman, Darragh F. Halpenny, Andrew J. Plodkowski, Stephanie L. Wu, Mark G. Kris et al. · 2021 · British Journal of Cancer
90. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer
    Yan Chen, Zijun Chen, Rui Chen, Cheng Fang, Chu Zhang, Mei Qing Ji, Xin Yang · 2022 · Future Oncology
91. HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC
    Helena Alexandra Yu, James Chih‐Hsin Yang, Hidetoshi Hayashi, Yasushi Goto, Enriqueta Felip, Martin Reck, Michele Vigliotti, Qian Dong, Frederique Cantero, Pang‐Dian Fan et al. · 2023 · Future Oncology
92. Targeted Therapy for Non-Small Cell Lung Cancer
    Zorawar Singh Noor, Amy Lauren Cummings, McKenna M. Johnson, Marshall L. Spiegel, Jonathan Wade Goldman · 2020 · Seminars in Respiratory and Critical Care Medicine
93. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
    Nathaniel Edward Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou, Rami Manochakian · 2021 · Frontiers in Oncology
94. Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings
    Taro Yoneda, Takashi Sone, Hayato Koba, Kazuhiko Shibata, Junya Suzuki, Mayuko Tani, Masaru Nishitsuji, Koichi Nishi, Takafumi Kobayashi, Hiroki Shirasaki et al. · 2022 · Clinical Lung Cancer
95. CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr -Mutant Lung Cancer
    Kazuya Nishii, Kadoaki Ohashi, Shuta Tomida, Takamasa Nakasuka, Atsuko Hirabae, Sachi Okawa, Jun Nishimura, Hisao Higo, Hiromi Watanabe, Hirohisa Kano et al. · 2022 · Cancer Immunology Research
96. Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
    Kostas A. Papavassiliou, Georgios Marinos, Athanasios G. Papavassiliou · 2023 · Cancers
97. Molecular pathology of non‐small cell carcinoma
    Yasushi Yatabe · 2023 · Histopathology
98. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
    Olivier Bylicki, Florian Guisier, I. Monnet, Helene Doubre, R. Gervais, Henri Janicot, Maurice Pérol, P. Fournel, R. Lamy, J.B. Auliac et al. · 2020 · Medicine
99. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak, Michael D. Lanuti, Alona Muzikansky, Julia K. Rotow, Pasi Antero Janne, Mari A. Mino-Kenudson, Steven Swanson, Cameron D. Wright et al. · 2024 · The Oncologist
100. Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer
     Juan Zhou, Jing Zhao, Qingzhu Jia, Qian Chu, Fei Zhou, Xiangling Chu, Wencheng Zhao, Shengxiang Ren, Caicun Zhou, Chunxia Su · 2021 · Frontiers in Oncology